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1. Introduction  
Because securing the safety of living kidney donor is essential to the continued success of 
this procedure, in this chapter we will review articles which focused not only on recipient 
outcome but also on living kidney donor to clarify what is known and what should be 
known in this field. 
2. Indication for living kidney donor  
For the perioperative and long-term safety, medical indication for living kidney donor is 
substantial issue. However, criteria for living kidney donor has been often derived 
empirically on a temporary basis and might vary by country, region and institute. Here, we 
summarize newly-developed guideline for the indication of living kidney donation which is 
internationally accepted such as the consensus of Amsterdam forum guideline (Delmonico 
F. 2005) and OPTN/UNOS guideline (Table 1). Then they were compared with the results of 
survey of US transplant center concerning evaluating living kidney donors (Mandelbrot DA, 
et al. 2007). 
2.1 Age 
There is no description of age limitation of living kidney donor in Amsterdam forum 
guideline. However age younger than 18 years old is attributed to contraindication in 
OPTN/UNOS guideline. Half of the institute did not set the upper limit of age, although 
widely accepted upper limit is 65 years old and some other institute set the cutoffs of 55, 
60,70 and 75 years old (Mandelbrot DA, et al. 2007).  
2.2 Obesity 
Obesity was defined by a body mass index (BMI) of >30 kg/m2. All potential donors should 
have BMI determined at initial evaluation because of data suggesting an association 
between obesity and kidney disease. In most guideline, BMI above 35 kg/m2 is thought to 
be contraindication especially when other comorbid conditions are present. And obese 
patients should be encouraged to lose weight before kidney donation and should not to 
donate if they have other associated comorbid conditions. According to the survey of US 
transplant centers, about one-half of programs use a BMI cutoff of 35 kg/m2, while 10% 
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exclude donors with BMI over 30 kg/m2 and 20% exclude donors with BMI over 40 kg/m2 
(Mandelbrot DA, et al. 2007). 
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Table 1. Contraindication for living kidney donor 
2.3 Renal function 
The first substantial issue is which measurement should be adapted to estimate renal 
function of potential living donors. Creatinine clearance calculated by 24-hour urine 
collections has been used most frequently, however, may under- or overestimate glomerular 
filtration rate (GFR) in patients with normal or near normal renal function. Estimated GFR 
values are easy way but not standardized in this population. These methods may be 
replaced or supplemented by inulin clearance in cases of borderline GFR determination 
although it is a complicated method. In most program, a GFR<80 ml/minute or 2 standard 
deviations below normal (based on age, gender, and BSA corrected to 1.73/m2) generally 
preclude donation (Delmonico F. 2005). According to the survey of US transplant center, few 
programs now have no specific cutoff, and no programs use 40 or 60 mL/min/1.73 m2 as 
cutoffs (Mandelbrot DA, et al. 2007). 
2.4 Proteinuria 
Proteinuria should be assessed as a standard part of the donor work up. Dipstick 
measurements of proteinuria are not enough in the assessment of a prospective living 
donor. According to the survey of US transplant center, most programs use a 24-hour urine 
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collection for protein. Some programs rely on a spot urine protein to creatinine ratio, and 
almost one-half of programs now use urinary albumin as a screen. As for cutoff level of 
proteinuria, more than 300 mg/24-hour of urineprotein is widely accepted as a 
contraindication to donation. Microalbuminuria determination is also reccomended, 
although its value as an international standard of evaluation for kidney donors has not been 
determined (Delmonico F. 2005).  
2.5 Hematuria 
Isolated microscopic hematuria may not be a contraindication to donation. Red blood cells 
(RBCs) with glomerular origin have a dysmorphic appearance observed by phase-contrast 
microscopy and automated RBC analysis. Patients with persistent microscopic hematuria 
should not be considered for kidney donation unless urine cytology and a complete urologic 
work up are performed. If urological malignancy and stone disease are excluded, a kidney 
biopsy may be indicated to rule out glomerular pathology such as IgA nephropathy. 
2.6 Hypertension 
Hypertension has been considered to be a contraindication in potential renal transplant 
donors. Some patients with easily controlled hypertension who meet other defined criteria 
may represent a low-risk group for development of kidney disease and may be acceptable 
as kidney donors. Hypertension exclusion criteria have become more flexible compared 
with previous survey (Bia MJ, et al. 1995). In recent survey, while 47% of programs exclude 
donors on any antihypertensive medication, 41% exclude donors if they are taking more 
than one medication, and 8% exclude donors taking more than two medications 
(Mandelbrot DA, et al. 2007). Blood pressure criteria tend to be looser if the donor is older, 
or if end organ damage is ruled out.  
2.7 Diabetes 
Diabetes is associated with an increased risk of postsurgical complications and future 
development of renal failure compared to the general population. Therefore, individuals 
with a history of diabetes or fasting blood glucose ≥126 mg/dl on at least two occasions or 2-
hour glucose with OGTT ≥200 mg/dl are thought to be contraindication for living kidney 
donation in Amsterdam forum guideline. OPTN/UNOS guideline adapts more strict cutoff 
level where 2hr BS≥140 are considered to be contraindication for living kidney donation. 
According to the survey of US transplant center, almost one-half of programs exclude 
donors based on elevated fasting blood glucose (FBG), but various cutoffs are used to define 
‘elevated’ (from >100 mg/dl to >120mg/dl). Most programs exclude based on abnormal 
oral glucose tolerance test or Type II diabetes. 
2.8 Dyslipidemia 
Dyslipidemia should be included along with other risk factors in donor risk assessment, but 
dyslipidemia alone does not generally exclude kidney donation. 
2.9 History of malignancy 
Living kidney donors should be screened by standard medical guidelines to exclude 
malignancy. A prior history of malignancy may only be acceptable for donation if prior 
treatment of the malignancy does not decrease renal reserve or place the donor at 
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increased risk for end stage renal disease (ESRD) and if prior treatment of malignancy 
does not increase the operative risk of nephrectomy. The history of melanoma, renal or 
urological malignancy, choriocarcinoma, hematologic malignancy, lung cancer, breast 
cancer and monoclonal gammopathy generally precludes living donation (Pham, PC, et al 
2007). 
3. Being donor with medical abnormality 
Due to the extreme shortage of organ donors worldwide, the indications for live kidney 
donation have been expanding in terms of medical status, and now include patients with 
mild hypertension, older age, and mild decline of renal function. Individuals with isolated 
medical abnormalities (IMAs) are undergoing living donor nephrectomy more frequently. 
Knowledge of health risks for these living donors is important for donor selection, informed 
consent and follow-up. One systematical review with living kidney donors with preexisting 
IMA showed perioperative outcomes for donors with and without IMAs were similar 
(Young A, et al 2008). However, few studies reported longer term rates of hypertension, 
proteinuria or renal function. Studies were frequently retrospective and without a 
comparison group. Centers may accept some IMA donors considering the small risk of 
ESRD developing as result of the IMA (Bia MJ, et al. 1995). Some long-term follow-up study 
of IMA donors will be described below.  
3.1 Being donor having hypertension 
When seeing the relatively short-term outcomes of hypertensive donors, white subjects with 
moderate, essential hypertension and normal kidney function have no adverse effects 
regarding blood pressure, GFR, or urinary protein excretion during the first year after living 
kidney donation. Although further studies are essential to confirm long-term safety, these 
data suggest that selected hypertensive patients may be accepted for living kidney donation 
(Textor SC, et al. 2004). 
One more study confirmed the long-term safety of hypertensive donors. When 674 live 
kidney donors were divided into two groups, survival rates in hypertension (HT)-group 
(N=54) by 20 years were equivalent as compared with non- HT group (N=620). Prevalence 
of renal dysfunction and ESRD were not increased in HT-group, while prevalence of HT 
and HT with medication was increased (Okamoto M. unpublished data). Those results 
demonstrated that those who have HT were able to donate their kidney safely with little 
major long-term morbidity by strict evaluation and careful postoperative follow-up.  
3.2 Being donor having proteinuria 
There were one long-term follow-up study of 70 renal outcome 25 years after donor 
nephrectomy in US single center (at the Cleveland Clinic). By this analysis patients with 
mild or borderline proteinuria before donation (0.160 g /24 hour) may represent a subgroup 
at particular risk for the development of significant proteinuria (>0.8 g /24 hour) 20 years or 
greater after donation (Goldfarb DA, et al. 2001).  
3.3 Being donor having glucose intolerance 
There were one report concerning long-term coutome of living kidney donors who 
donated kidneys having glucose intolerance (GI). In this study, 444 donor nephrectomies 
were divided into GI group and non-GI group according to the results of 75g-oral glucose 
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tolerance test (75g-OGTT). Survival rates in the GI group up to 20 years were equivalent 
to those in the non-GI group. None of the patients with diabetes mellitus (75g-OGTT: DM 
pattern, n=27) had developed severe diabetic complications or ESRD at a mean follow-up 
point of 88±71 (range, 14-225) months. These results suggested that individuals who have 
GI without diabetic complication may be able to donate their kidney safely with little 
major morbidity if strict evaluation is performed before transplant (Okamoto M, et al. 
2010).  
3.4 Transplant outcomes from isolated medical abnormality (IMA) donors 
According to the meta-analysis of 12 studies, recipients of kidneys from older donors had 
poorer 5-year patient and graft survival than recipients of kidneys from younger donors. 
However, few transplant outcomes were described for other IMA, namely, obesity, 
hypertension, reduced GFR, proteinuria and hematuria. This disconnect between donor 
selection and a lack of knowledge of recipient outcomes should give transplant decision-
makers pause and sets an agenda for future research (Iordanous Y, et al. 2009).  
4. Perioperative issue in living kidney donation 
The first major concern regarding living kidney donation is the incidence of perioperative 
deaths and serious surgical complications. Although it is considered to be a relatively safe 
procedure, risk of death for the donor is generally estimated as being around 0.02-0.03%. 
Perioperative mortality and complications of donor nephrectomy including pulmonary 
embolism, pneumothorax, and less seriously, wound infection, unexplained fever and 
urinary tract infection will be described below.  
4.1 Perioperative mortality 
Donor safety is of paramount importance in living donor transplantation. Yet, living donor 
deaths actually occur (Ratner LE, et al. 2010). According to the survey of 171 United States 
kidney transplant centers, two donors (0.02%) out of 10,828 living donors died from surgical 
complications between 1999 and 2001 (Matas AJ, et al. 2003). However, in separate report 
from the various transplant center, there are little report of a donor death (Siebels M,et al. 
2003, Jones KW, et al. 1997, Johnson EM, et al. 1997, Blohme I, et al. 1992). 
4.2 Possible surgical complication 
There are some surgical complication specific to living donor nephrectomy. Special care 
must be taken to prevent them. 
4.2.1 Deep vein thrombosis/pulmonary embolism  
Deep vein thrombosis/pulmonary embolism are most serious complication following living 
donor nephrectomy. Actually one specified death was caused by pulmonary embolism 
(Matas AJ, et al. 2003). We reported one case of pulmonary embolism which was diagnosed 
in relatively early period and successfully recovered with anti-coagulant therapy and 
transient mechanical ventilation (Ushigome H, et al. 2003). It is very important for surgeons 
to realize that this can develop in any case of living donor nephrectomy. Every effort should 
be made to prevent it by enough hydration, intermittent pneumatic compression (IPC) and, 
if necessary, prophylactic anti-coagulant therapy.  
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4.2.2 Pneumothorax  
Pneumothorax also occurs because of anatomical reason, which sometime needs pleural 
drainage. The report from US single center (University of Minnesota) described 13 (1.5%) 
pneumothoraces (6 required intervention, 7 resolved spontaneously) among 871 living 
donor nephrectomies (Johnson EM, et al. 1997). 
4.2.3 Bleeding  
Bleeding is the most common cause of reoperation especially laparoscopic nephrectomy. 
According to the survey of United States kidney transplant centers, 26 donors (0.24%) out of 
10,828 living donors needed reoperation because of bleeding (Matas AJ, et al. 2003). By a 
report of Swedish single center through a retroperitoneal approach, there were 5 cases 
(1.02%) of postoperative haemorrhage requiring reoperation out of 490 living donor 
nephrectomies (Blohme I, et al. 1992). 
4.2.4 Incisional hernia  
Incisional hernia can occur as in other laparotomic surgery and needs reoperation. 
According to the survey of United States kidney transplant centers, 22 donors (0.20%) out of 
10,828 living donors needed reoperation because of hernia (Matas AJ, et al. 2003). 
4.2.5 Femoral nerve compression  
Femoral nerve compression may occur because it exists on the psoas muscle and it can be 
compressed by would retractor. 
4.2.6 Wound infections, hematomas or seromas  
Wound infections, hematomas or seromas happen most frequently after living donor 
nephrectomy as a minor complication. They usually resolve without major operation. 
4.2.7 Pneumonias, atelectasis and urinary tract infections  
Pneumonias and atelectasis also happens as a complication of general anesthesia. They tend 
to occur at an opposite site of nephrectomy because of lateral recumbent position. Urinary 
tract infections also happen as in other surgical procedure due to insertion of urethral 
catheter. 
4.3 Risk factors for perioperative complications 
Transplant professionals should avoid possible risk for living kidney donors. A couple of 
report analyzed the risk factor for them. According to analysis of live donors drawn from a 
mandated national registry of 80 347 live kidney donors in the United States between 1994 
and 2009, surgical mortality was higher in men than in women (RR=3.0), in black vs. white 
and Hispanic individuals (RR=3.1), and in donors with hypertension vs. without 
hypertension (RR=27.4) (Segev DL, et al. 2010). The report from US single center (University 
of Minnesota) described that the analysis, by logistic regression, among 871 living donor 
nephrectomies identified significant risk factors for perioperative complications were male 
gender (vs. female), pleural entry (vs. no pleural entry), and weight > or = 100 kg (vs. < 100 
kg) (Johnson EM, et al. 1997). 
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5. Long-term follow-up of living kidney donor -Survival, renal function, 
complication 
The long-term consequences after kidney donation are not fully understood. However, most 
long-term follow-up studies of living kidney donors find no decrease in long-term survival. 
And most of the data suggested that the donors had normal renal function, with an 
incidence of hypertension comparable to that expected in the age-matched general 
population, while other demonstrated that donor nephrectomy is associated with mild 
proteinuria and hypertension. The Long-term follow-up study of living kidney donor 
concerning survival rate, renal function and various complications will be described 
including our Japanese experiences (Table 2). 
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Table 2. Report of long-term outcome after living kidney donation 
5.1 Long-term survival following living kidney donation 
Most long-term follow up studies of living kidney donors find no decrease in long-term 
survival. By analysis of 430 previous living kidney donors in Swedish single center, the 
survival rate of 20 years was 29% better than the expected survival rate calculated by 
using national registers. They concluded that the better survival among donors is 
probably due to the fact that only healthy persons are accepted for living kidney donation 
(Fehrman-Ekholm I, et al. 1997). Moreover, the analysis of 481 previous Japanese living 
kidney donors also showed that the survival rate of kidney donors was better than the 
age- and gender-matched cohort from the general population, and the patterns and causes 
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of death were similar with the general population (Okamoto M, et al. 2009). The study of 
larger numbers of donors as many as 3698 who donated kidneys during the period from 
1963 through 2007 for a longer follow-up period in US single institute (University of 
Minnesota) also ascertained that the survival of kidney donors was similar to that of 
controls who were matched for age, sex, and race or ethnic group (Ibrahim, HN, et al. 
2009). The overall evidence suggests that living kidney donors have survival similar to 
that of non-donors. 
5.2 Hypertension following living kidney donation 
Hypertension is thought to be one of major concerns following living kidney donation. 
However, a couple of study demonstrated no increase of hypertension after living donor 
nephrectomy. By a 15-year experience on 162 living donors in Italy, Long-term incidence of 
hypertension in living donors was similar to the general population (Sansalone CV, et al. 
2006). Furthermore, the analysis of 402 donor nephrectomy in Sweden showed that, 
although hypertension was present in 38% of the donors, the age-adjusted prevalence of 
hypertension among donors was not higher than in the general population (Fehrman-
Ekholm I, et al. 2001). 
On the other hands, some study demonstrated increase of hypertension after living donor 
nephrectomy. Another analysis of 75 donors, in US single center (University of Missouri), 
showed that the prevalence of hypertension was significantly increased compared with 
age/sex matched data from epidemiological studies of the general population, especially in 
those over the age of 55 years (Saran R, et al. 1997 ). Also, in a live kidney donor cohort with 
a 93% retrieval rate of the 152 donors, mean blood pressure had increased from 125 ± 15/79 
± 11 to 134 ± 19/81 ± 9 mmHg (p < 0.01) which remained significantly below normal. 
(Gossmann J, et al. 2005). One Meta-analysis showed kidney donors may have a 5 mmHg 
increase in blood pressure within 5 to 10 years after donation over that anticipated with 
normal aging (Boudville N, et al. 2006). Future controlled, prospective studies with long 
periods of follow-up will better delineate the risk of hypertension following living kidney 
donation. 
5.3 Proteinuria following living kidney donation 
Most reported data suggested that proteinuria increased in living kidney donor population, 
although follow-up period and measurement of proteinuria and/or microalbuminuria 
differed by report. 
German experience at a single center of 102 living kidney donors for 35 years showed 
microalbuminuria was found in 22.6% of the donors (Schostak M, et al. 2004). Another study 
showed, in a live kidney donor cohort with a 93% retrieval rate of the 152 donors, fifty six 
percent of donors developed proteinuria (>150 mg/day), but only 10% had albuminuria 
(Gossmann J, et al. 2005). By analysis of 402 outcome after donor nephrectomy in Sweden, 
significant proteinuria (> or =1.0 g/L) was found in 3% and slight proteinuria (<1.0 g/L) in 
9% of the donors and proteinuria was associated with hypertension and a lower GFR 
(Fehrman-Ekholm I, et al. 2001). 
One Meta-analysis, which analyzed a total of 5048 donors from forty-eight studies with an 
average follow-up of 7 years after donation (range 1-25 years), demonstrated that the 
average 24-h urine protein was 154 mg/day and concluded that kidney donation results in 
small increases in urinary protein. (Garg AX, et al. 2006).  
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5.4 Renal function following living kidney donation 
Renal function is the greatest concerns at a long time after living kidney donation. In a 
report from Saudi Arabia of 25 living kidney donors, total kidney function measured as 
creatinine clearance showed significant drop by 36% of the pre donated value. However, 
remaining kidney clearance increased by an average of 34% of the pre donated level as 
measured by Tc 99m DTPA renography. Compensatory hypertrophy of the remaining 
kidney measured by ultrasound attributed to an increase in the renal volume of 15% 
(Shehab AB, et al. 1994 ). Other investigator shows 25% decrease of GFR with mean time 
after uninephrectomy of 11 years. (Gossmann J, et al. 2005 ), and 27% decrease of with mean 
patient follow-up of 25 years (Goldfarb DA, et al. 2001 ). 
In a Swedish study, the average estimated GFR (12 years after donation) was 72±18% of the 
age-predicted value. The ratio of the estimated to the predicted GFR showed no correlation 
to the time since donation, indicating that there is no accelerated loss of renal function after 
donation (Fehrman-Ekholm I, et al. 2001 ). These results demonstrated that although living 
kidney donor lose GFR by 15-25%, they usually do not show the accelerated loss of renal 
function if they do not have risk factor for chronic renal disease (CKD). One unique study 
examined renal function >20 years after donation by comparing that with siblings. They 
showed no significant difference in serum creatinine (1.1±0.01 vs 1.1±0.03 mg/dl), blood 
urea nitrogen (17±0.5 vs 17±1.2 mg/dl) and creatinine clearance (82±2 vs 89±3.3 ml/min) 
between 57 donors (mean age 61±1) and 65 siblings (mean age 58±1.3) (Najarian JS, et al. 
1992 ).  
5.5 ESRD in previous donor  
Although the Swiss Organ Living Donor Health Registry showed no ESRD in 737 living 
kidney donors between 1993 and January 2005 (Thiel GT, et al. 2005), there were 
considerable reports of ESRD of previous kidney donor as below. 
In a survey which used the Organ Procurement and Transplantation Network (OPTN) 
database, a total of 56 previous living donors were identified as having been subsequently 
listed for cadaveric kidney transplantation. They concluded that living renal donation has 
long-term risks that may not be apparent in the short term and that the numbers reported 
underestimate the actual number of living donors with renal failure, because they include 
only patients listed for a kidney transplant. (Ellison MD, et al. 2002). In analysis of 402 donor 
nephrectomy in Sweden, no donor died in uremia or had dialysis treatment before death. 
However, three donors developed renal disease, and one was in dialysis treatment. In two 
of these cases, hereditary factors were possibly involved (Fehrman-Ekholm I, et al. 2001). In 
Mexican experience, they present four kidney donors who developed ESRD thereafter, three 
becoming kidney recipients (Gracida C, et al. 2001). Other two case reports described kidney 
donors who developed ESRD (Ladefoged J, et al. 1992, al Shohaib S, et al. 1995). By analysis 
of 464 outcomes after donor nephrectomy at University of Minnesota, 84 had died and 380 
were alive. Of the 84 donors who had died, three were known to have had kidney failure. Of 
the 380 still alive, three had abnormal kidney function and two had undergone 
transplantation (Ramcharan T, et al. 2002).  
One study carefully investigated the association between postoperative clinical courses and 
changes in renal function in eight donors who developed chronic kidney disease (CKD) 
stage 5 or ESRD. According to their findings, except for one donor who developed ESRD 
caused by a traffic accident, none of the donors developed progressive renal dysfunction 
immediately after donation. Their renal functions remained stable for a long period, but 
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started to decline after developing new comorbidities, especially risk factors known as 
progression factors (proteinuria or hypertension) or accelerating factors (cardiovascular 
event or infection) of CKD (Kido R, et al. 2009). However, the overall evidence suggests that 
their risk of ESRD is not increased. 
6. Ethical issue and quality of life (Q.O.L.) in living kidney donation 
Most published reports have indicated healthy psychological status and improved quality of 
life (Q.O.L.) in living kidney donors. However, there have been some reports of depression 
and disrupted family relationships after kidney donation. The reasons of negative results 
were mainly related to poor outcome of the kidney recipient, or long-lasting major pain or 
disappointment about medical handling before and after organ donation. Ethical issue and 
Q.O.L. in living kidney donation will be described. 
6.1 Ethical issue in living kidney donation 
Not only medical aspect but also ethical aspect is very important part to continue living 
kidney transplantation. The general public's concerns of living kidney donation is the length 
of a hospital stay, out-of-pocket expenses, size and appearance of a scar, and the donor risk 
of developing kidney failure (Boulware LE, et al. 2002 ). In this respect, it is quite important 
process to inform prospective donor of these issues. Especially, a long-term medical risk 
with potential living donors is a vital aspect of informed consent. According to a survey of 
203 practitioners in 35 countries, risks of hypertension, proteinuria or kidney failure 
requiring dialysis were frequently discussed (usually over 80% of practitioners discussed 
each medical condition). However, many practitioners do not believe these risks are 
increased after donation, with surgeons being less convinced of long-term sequelae 
compared with nephrologists. Thus, transplant professionals vary in the long-term risks 
they communicate to potential donors. (Housawi AA, et al. 2007). 
Moreover, the expansion of living donor kidney transplantation to include significant 
numbers of donors with little to no preexisting relationship to the candidate has caused 
concern in the medical community regarding as donor psychological status, motivation, 
knowledge about donation and the potential for undue pressure to donate under some 
circumstances. (Dew MA, et al. 2007). Another rare but delicate issue in living-related 
kidney donation is discovering misattributed paternity. In a survey, the prevalence of 
misattributed paternity ranges between approximately 0.25% and 0.5% of all living kidney 
donations. Opinions about revealing this information were quite variable by practitioners 
(Young A, et al. 2009). 
6.2 Quality of life (Q.O.L.) in living kidney donation 
Same as medical risk, Q.O.L. in living kidney donors is substantial issue to continue this 
procedure. According to the experience in German single institute of 102 living kidney 
donors, everyday life was managed as well as before surgery after 2-4 wk by the highest 
percentage (42%) of patients, but working capacity was only regained after 1-3 months by a 
comparable percentage (44%). Forty-six percent had a very good and 33% a good feeling 
after the kidney donation. The relationship to the recipient had intensified in most cases. 
Ninety-one percent would again decide in favor of a donation (Schostak M, et al. 2004). By 
another survey, majority of living kidney donors had an excellent Q.O.L. As a group, they 
scored higher than the national norm on the SF-36, a standardized Q.O.L health 
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questionnaire. However, 4% were dissatisfied and regretted the decision to donate. Further, 
4% found the experience extremely stressful and 8% very stressful. Multivariate analysis 
found that relatives other than first degree and donors whose recipient died within 1 year of 
transplant were more likely to say they would not donate again if it were possible. Further, 
donors who had perioperative complications and female donors were more likely to find the 
overall experience more stressful (Johnson EM, et al. 1999). 
Women considering kidney donation frequently ask whether a nephrectomy will impact 
their ability to have children (Nevis IF, et al. 2009). There is a single-center survey which 
described 490 pregnancies in 239 donors after donation. Compared to pregnancies before 
donation, pregnancies after donation had increased rates of gestational diabetes (0.7% vs. 
2.7%), gestational hypertension (0.6% vs. 5.7%), preeclampsia (0.8% vs. 5.5%), prematurity 
(4.0% vs. 7.1%) and fetal loss (11.3% vs.19.2%). The authors reported that these incidences of 
adverse events observed in donors were similar or better than expected levels for the 
general population (Ibrahim H et al. 2009). Therefore, pregnancy after kidney donation is 
not necessarily contraindication although it is better to avoid. 
7. Financial Issue in living kidney donation 
Many nations have programs that help living donors with their financial costs while donors 
in other regions of the world are without support. Moreover some living kidney donors 
encounter difficulties obtaining life insurance, despite the surveys of insurance companies 
reporting otherwise.  
7.1 Reimbursement for living kidney donation 
The financial risk of living donation is theoretically well covered by different insurances. 
However, some of the donors had to cover some expenses by themselves (Wolters HH, et al. 
2003). It is proposed to reimburse donor risk by a package of specific benefits (life insurance, 
health insurance and a small amount of cash) to minimize hazard and ensure donor 
interests. It will fund medical follow-up and enable data collection so that long-term risk can 
be accurately assessed (Gaston RS, et al. 2006). 
One international research network examined legislation and programs that facilitate 
reimbursement, focusing on policy mechanisms, eligibility criteria, program duration and 
types of expenses reimbursed. According to their results, among 40 countries, 
reimbursement is expressly legal in 16, unclear in 18, unspecified in 6 and expressly 
prohibited in 1. Donor reimbursement programs exist in 21 countries; 6 have been enacted 
in the last 5 years. Lost income is reimbursed in 17 countries, while travel, accommodation, 
meal and childcare costs are reimbursed in 12 to 19 countries. Ten countries have 
comprehensive programs, where all major cost categories are reimbursed to some extent. 
These programs differ in operation and scope. Donors in other regions of the world are 
without support (Sickand M, et al. 2009). Effort should be taken to establish reimbursement 
system to facilitate living kidney donation where this procedure is performed. 
7.2 Life insurance after living kidney donation 
Being an organ donor may affect one's ability to obtain life, disability and health insurance. 
According to a systematic review, almost all companies would provide life and health 
insurance to living organ donors, usually with no higher premiums. However, concern 
about insurability was still expressed by 2%–14% of living organ donors in follow-up 
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studies, and 3%–11% of donors actually encountered difficulties with their insurance (Yang 
RC, et al. 2007). 
In another study, researchers contacted offices of life insurance companies in five major 
cities in Canada to obtain life insurance for fictitious living kidney donors and paired 
controls. As a result, all donor and control profiles received a quote, with no significant 
difference in the premium quoted. More time was spent on the phone for donor compared 
to control profiles, although difference was small. Age, gender, family history of kidney 
disease and new-onset hypertension had no further effect on donor insurability in 
regression analysis. They found no evidence that kidney donors were disadvantaged in the 
first step of applying for life insurance (Yang RC, et al. 2009). 
8. Conclusion 
Because securing the safety of donor is essential to the continued success of living kidney 
transplantation, we have reviewed important issues, namely, indication, donation with 
medical abnormality, perioperative problem, long-term follow-up, ethical issue, Q.O.L. and 
financial issue in living kidney donation. The background quite differ by region, therefore, it 
seems to be difficult to build a international standard. Regular follow-up of kidney donors is 
recommended in order to manage their complications effectively and to detect health 
problem early in those who may develop it. National registry is necessary to enable data 
collection so that long-term risk can be accurately assessed. 
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